Enzyme-Triggered In Situ Assembly of Fe

Jianjun Kang, Yuanchun Chen, Zongcheng Shu, Cuimin Wu, Fang Ke

Abstract read

In one paragraph

Article in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jianjun KangFujian Provincial Key Laboratory of Natural Medicine Pharmacology, Institute of Materia Medica, School of Pharmacy, Fujian Medical University, Fuzhou 350004, China.

Yuanchun ChenDepartment of Gastroenterology, Fuzhou University Affiliated Provincial Hospital, Fuzhou 350001, China.ORCID 0009-0005-1868-0272

Zongcheng ShuFujian Provincial Key Laboratory of Natural Medicine Pharmacology, Institute of Materia Medica, School of Pharmacy, Fujian Medical University, Fuzhou 350004, China.

Cuimin WuFujian Provincial Key Laboratory of Natural Medicine Pharmacology, Institute of Materia Medica, School of Pharmacy, Fujian Medical University, Fuzhou 350004, China.

Fang KeFujian Provincial Key Laboratory of Natural Medicine Pharmacology, Institute of Materia Medica, School of Pharmacy, Fujian Medical University, Fuzhou 350004, China.ORCID 0000-0002-5970-2512

Funding

Fujian Provincial Key Laboratory of Hepatic Drug Research KFLX2024002Natural Science Foundation of Fujian Province 2025J01702, 2025J01708

6 · The paper itself

Abstract

Acid phosphatase (ACP) is a clinically important enzyme whose early-stage detection is hindered by its extremely low abundance, nonspecific tissue distribution, and rapid loss of activity under conventional analytical conditions. Herein, we present a target-driven in situ nanozyme synthesis strategy that enables rapid and ultrasensitive point-of-care testing (POCT) of ACP. In this approach, ACP catalyzes the hydrolysis of L-ascorbic acid 2-phosphate sesquimagnesium (AAPS), producing ascorbic acid (AA). The generated AA partially reduces Fe

Indexed as

Acid PhosphataseBiosensing TechniquesAscorbic AcidBenzidinesColorimetryHumansHydrogen PeroxideLimit of DetectionMagnetite NanoparticlesPoint-of-Care SystemsPoint-of-Care TestingRapid Diagnostic TestsSmartphone3,3',5,5'-tetramethylbenzidineAcid PhosphataseAscorbic AcidBenzidinesHydrogen PeroxideMagnetite Nanoparticlesacid phosphatasecolorimetric assayFe3O4 nanozymesperoxidasesmartphone detection

Identifiers

PMID42345893

DOI10.3390/bios16060337

PMCPMC13296935

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.